(a) Specifications. Type A medicated articles containing 20 or 50 grams per pound lincomycin as lincomycin hydrochloride.
(b) Sponsor. See No. 054771 in Sec. 510.600(c) of this chapter.
(c) Related tolerances. See Sec. 556.360 of this chapter.
(d) Special considerations--(1) Labeling of Type A medicated articles and Type B and Type C medicated feeds containing lincomycin shall bear the following directions: ``CAUTION: Do not allow rabbits, hamsters, guinea pigs, horses, or ruminants access to feeds containing lincomycin. Ingestion by these species may result in severe gastrointestinal effects.''
(1) Labeling of Type A medicated articles and Type B and Type C medicated feeds containing lincomycin shall bear the following directions: ``CAUTION: Do not allow rabbits, hamsters, guinea pigs, horses, or ruminants access to feeds containing lincomycin. Ingestion by these species may result in severe gastrointestinal effects.''
(2) Labeling of Type A medicated articles and Type B and Type C medicated feeds containing lincomycin intended for use in swine shall bear the following directions: ``CAUTION: Occasionally, swine fed lincomycin may within the first 2 days after the onset of treatment develop diarrhea and/or swelling of the anus. On rare occasions, some pigs may show reddening of the skin and irritable behavior. These conditions have been self-correcting within 5 to 8 days without discontinuing the lincomycin treatment.''
(3) Labeling of Type A medicated articles and single-ingredient Type B and Type C medicated feeds containing lincomycin intended for use in swine shall bear the following directions:
(i) No. 054771: ``CAUTION: The effects of lincomycin on swine reproductive performance, pregnancy, and lactation have not been determined. Not for use in swine intended for breeding when lincomycin is fed at 20 grams per ton of complete feed.''
(ii) No. 051311:``CAUTION: Not to be fed to swine that weigh more than 250 lb.''
(e) Conditions of use--(1) Chickens. It is used in feed as follows: ----------------------------------------------------------------------------------------------------------------
(i) 2.................................... Broilers: For control of As lincomycin hydrochloride 054771
necrotic enteritis caused monohydrate..
by Clostridium spp. or
other susceptible
organisms..(ii) 2 to 4.............................. Broilers: For increased rate As lincomycin hydrochloride 054771
of weight gain and improved monohydrate..
feed efficiency..----------------------------------------------------------------------------------------------------------------
(2) Swine. It is used in feed as follows:
----------------------------------------------------------------------------------------------------------------
(i) 20................................... Growing-finishing swine: For Feed as sole ration......... 054771
increased rate of weight
gain..(ii) 40.................................. 1. For control of swine Feed as sole ration; for use 054771
dysentery.. in swine on premises with a
history of swine dysentery
but where symptoms have not
yet occurred, or following
use of lincomycin at 100
grams (g)/ton for treatment
of swine dysentery..
2. For control of porcine Feed as sole ration, or 054771
proliferative enteropathies following use of lincomycin
(ileitis) caused by at 100 g/ton for control of
Lawsonia intracellularis.. porcine proliferative
enteropathies (ileitis)..(iii) 100................................ 1. For treatment of swine Feed as sole ration for 3 054771
dysentery.. weeks or until signs of
disease disappear..
2. For control of porcine Feed as sole ration for 3 054771
proliferative enteropathies weeks or until signs of
(ileitis) caused by disease disappear..
Lawsonia intracellularis..(iv) 200................................. For reduction in the Feed as sole ration for 3 054771
severity of swine weeks..
mycoplasmal pneumonia
caused by Mycoplasma
hyopneumoniae..----------------------------------------------------------------------------------------------------------------
(3) Lincomycin may also be used in combination with:
(i) Amprolium and ethopabate as in Sec. 558.58.
(ii) Clopidol as in Sec. 558.175.
(iii) Decoquinate as in Sec. 558.195.
(iv) Fenbendazole as in Sec. 588.258.
(v) Halofuginone as in Sec. 558.265.
(vi) Ivermectin as in Sec. 558.300.
(vii) Lasalocid sodium as in Sec. 558.311.
(viii) Monensin as in Sec. 588.355.
(ix) Nicarbazin alone and with narasin as in Sec. 558.366.
(x) Pyrantel as in Sec. 558.485.
(xi) Robenidine as in Sec. 558.515.
(xii) Salinomycin as in Sec. 558.550.
(xiii) Zoalene as in Sec. 558.680. [40 FR 13959, Mar. 27, 1975]
Editorial Note: For Federal Register citations affecting Sec. 558.325, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at www.fdsys.gov.